TCID is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L3 (UCH-L3) with an IC50 ~0.6 μM. It has ~125-fold greater selectivity over UCH-L1 (ubiquitin C-terminal hydrolase L1, IC50 ~75 μM). TCID can diminish glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.
CAS Number: 30675-13-9
Molecular Weight: 283.92
Chemical Name: 4,5,6,7-Tetrachloro-1H-Indene-1,3(2H)-dione
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO up to 50 mM
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
TCID was used at 10-30 µM final concentration in various in vitro assays.
- Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
- e Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. (2013) PLoS One. 8(3):e58863.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.